SCHEMBL4980666

SCHEMBL4980666

Cc1ccc(OCC(=O)N2CCc3cnc(N4CCN(C5CCC5)CC4)nc3CC2)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
LMNA P02545 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HSP90AB1 P08238 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 3/20 0.41
NPC1 O15118 2/20 0.41
GAA P10253 2/20 0.41
TSHR P16473 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
TLR4 O00206 1/20 0.40
TLR9 Q9NR96 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4976178 0.93 MEN1 (0.50) SMN1; SMN2MEN1KMT2ALMNAKDM4E
SCHEMBL4980423 0.92 LMNA (0.56) SMN1; SMN2MEN1KMT2ALMNAKDM4E
SCHEMBL14346546 0.90 HSP90AB1 (0.40) SMN1; SMN2MEN1KMT2ALMNAKDM4E
SCHEMBL4979744 0.90 MEN1 (0.50) SMN1; SMN2MEN1KMT2ALMNAKDM4E
SCHEMBL4980557 0.88 KDM4E (0.49) SMN1; SMN2MEN1KMT2ALMNAKDM4E
SCHEMBL4978179 0.87 NPSR1 (0.58) SMN1; SMN2MEN1KMT2ALMNAKDM4E
SCHEMBL4975411 0.87 MEN1 (0.47) SMN1; SMN2MEN1KMT2ALMNAKDM4E
SCHEMBL4978277 0.85 HTT (0.52) SMN1; SMN2LMNAKDM4EHSP90AB1NPSR1
SCHEMBL4976502 0.85 KDM4E (0.50) SMN1; SMN2MEN1KMT2AKDM4EHSP90AB1
SCHEMBL4978729 0.85 LMNA (0.45) SMN1; SMN2MEN1KMT2ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES HRH3, HRH4, HRH2 SMN1; SMN2 3880/4885MEN1 4419/4885KMT2A 1417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.